(51) International Patent Classification 7: C07K 7/56, A61K 38/12

(11) International Publication Number: WO 00/12540
(43) International Publication Date: 9 March 2000 (09.03.00)

(21) International Application Number: PCT/US99/19066
(22) International Filing Date: 18 August 1999 (18.08.99)
(30) Priority Data: 60/098,267 28 August 1998 (28.08.98) US

(71) Applicant (for all designated States except US): ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).

(72) Inventors; and
(75) Inventors/Applicants (for US only): MOSER, Brian, Allen [US/US]; 751 West Hanna Avenue, Indianapolis, IN 46217 (US). BAKER, Jeffrey, Clayton [US/US]; 4430 North Pennsylvania Avenue, Indianapolis, IN 46205 (US).


(54) Title: REVERSIBLE BORONATE COMPLEXES OF 1,2-CIS-DIOL CYCLIC-PEPTIDES

(57) Abstract

Reversible boronate or boronate complexes of 1,2-cis-diol cyclic-peptides and their use as a means for purification, isolation, stabilization and/or water solubilization of their respective parent 1,2-cis-diol cyclic-peptide is described. A method for forming the boronate adducts is also described. The method is particularly useful for forming boronate adducts of hydrophobic Echinocandins compounds to increase their water solubility. Pharmaceutical formulations and treatments based on the reversible boronate or boronate complexes of active 1,2-cis-diol cyclic-peptides (e.g., Echinocandin antifungal compounds) are also described.


Published

With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.
FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>AL</td>
<td>Albania</td>
<td>ES</td>
<td>Spain</td>
<td>LS</td>
<td>Lesotho</td>
</tr>
<tr>
<td>AM</td>
<td>Armenia</td>
<td>FI</td>
<td>Finland</td>
<td>LT</td>
<td>Lithuania</td>
</tr>
<tr>
<td>AT</td>
<td>Austria</td>
<td>FR</td>
<td>France</td>
<td>LU</td>
<td>Luxembourg</td>
</tr>
<tr>
<td>AU</td>
<td>Australia</td>
<td>GA</td>
<td>Gabon</td>
<td>LV</td>
<td>Latvia</td>
</tr>
<tr>
<td>AZ</td>
<td>Azerbaijan</td>
<td>GB</td>
<td>United Kingdom</td>
<td>MC</td>
<td>Monaco</td>
</tr>
<tr>
<td>BA</td>
<td>Bosnia and Hercegovina</td>
<td>GE</td>
<td>Georgia</td>
<td>MD</td>
<td>Republic of Moldova</td>
</tr>
<tr>
<td>BB</td>
<td>Barbados</td>
<td>GH</td>
<td>Ghana</td>
<td>MG</td>
<td>Madagascar</td>
</tr>
<tr>
<td>BE</td>
<td>Belgium</td>
<td>GN</td>
<td>Guinea</td>
<td>MK</td>
<td>The former Yugoslav</td>
</tr>
<tr>
<td>BF</td>
<td>Burkina Faso</td>
<td>GR</td>
<td>Greece</td>
<td>ML</td>
<td>Mali</td>
</tr>
<tr>
<td>BG</td>
<td>Bulgaria</td>
<td>HU</td>
<td>Hungary</td>
<td>MN</td>
<td>Mongolia</td>
</tr>
<tr>
<td>BJ</td>
<td>Benin</td>
<td>IE</td>
<td>Ireland</td>
<td>MR</td>
<td>Mauritania</td>
</tr>
<tr>
<td>BR</td>
<td>Brazil</td>
<td>IL</td>
<td>Israel</td>
<td>MW</td>
<td>Malawi</td>
</tr>
<tr>
<td>BY</td>
<td>Belarus</td>
<td>IS</td>
<td>Iceland</td>
<td>MX</td>
<td>Mexico</td>
</tr>
<tr>
<td>CA</td>
<td>Canada</td>
<td>IT</td>
<td>Italy</td>
<td>NE</td>
<td>Niger</td>
</tr>
<tr>
<td>CF</td>
<td>Central African Republic</td>
<td>JP</td>
<td>Japan</td>
<td>NL</td>
<td>Netherlands</td>
</tr>
<tr>
<td>CG</td>
<td>Congo</td>
<td>KE</td>
<td>Kenya</td>
<td>NO</td>
<td>Norway</td>
</tr>
<tr>
<td>CH</td>
<td>Switzerland</td>
<td>KG</td>
<td>Kyrgyzstan</td>
<td>NZ</td>
<td>New Zealand</td>
</tr>
<tr>
<td>CI</td>
<td>Côte d’Ivoire</td>
<td>KP</td>
<td>Democratic People's</td>
<td>PL</td>
<td>Poland</td>
</tr>
<tr>
<td>CM</td>
<td>Cameroon</td>
<td>KR</td>
<td>Republic of Korea</td>
<td>PT</td>
<td>Portugal</td>
</tr>
<tr>
<td>CN</td>
<td>China</td>
<td>KZ</td>
<td>Kazakhstan</td>
<td>RO</td>
<td>Romania</td>
</tr>
<tr>
<td>CU</td>
<td>Cuba</td>
<td>LC</td>
<td>Saint Lucia</td>
<td>RU</td>
<td>Russian Federation</td>
</tr>
<tr>
<td>CZ</td>
<td>Czech Republic</td>
<td>LI</td>
<td>Liechtenstein</td>
<td>SD</td>
<td>Sudan</td>
</tr>
<tr>
<td>DE</td>
<td>Germany</td>
<td>LK</td>
<td>Sri Lanka</td>
<td>SE</td>
<td>Sweden</td>
</tr>
<tr>
<td>DK</td>
<td>Denmark</td>
<td>LR</td>
<td>Liberia</td>
<td>SG</td>
<td>Singapore</td>
</tr>
<tr>
<td>EE</td>
<td>Estonia</td>
<td>SI</td>
<td>Slovenia</td>
<td>SK</td>
<td>Slovakia</td>
</tr>
<tr>
<td>SN</td>
<td>Senegal</td>
<td>SZ</td>
<td>Swaziland</td>
<td>TD</td>
<td>Chad</td>
</tr>
<tr>
<td>TG</td>
<td>Togo</td>
<td>TJ</td>
<td>Tajikistan</td>
<td>TR</td>
<td>Turkey</td>
</tr>
<tr>
<td>TM</td>
<td>Turkmenistan</td>
<td>TT</td>
<td>Trinidad and Tobago</td>
<td>UA</td>
<td>Ukraine</td>
</tr>
<tr>
<td>TG</td>
<td>Togo</td>
<td>UG</td>
<td>Uganda</td>
<td>US</td>
<td>United States of America</td>
</tr>
<tr>
<td>UZ</td>
<td>Uzbekistan</td>
<td>VN</td>
<td>Viet Nam</td>
<td>YU</td>
<td>Yugoslavia</td>
</tr>
<tr>
<td>ZW</td>
<td>Zimbabwe</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
REVERSIBLE BORONATE COMPLEXES OF 1,2-CIS-DIOL CYCLIC-PEPTIDES

FIELD OF THE INVENTION

The present invention relates to the formation of reversible borate or boronate complexes of 1,2-cis-diol cyclic-peptides and their use as a means for purification, isolation, stabilization and/or water solubilization of their respective parent 1,2-cis-diol cyclic-peptide, in particular, Echinocandin compounds and derivatives thereof. The invention also relates to pharmaceutical formulations and treatments based on the reversible borate or boronate complexes described above.

BACKGROUND OF THE INVENTION

Macromolecules and in particular cyclic peptides such as those related to the antifungal agent Echinocandin B (ECB) tend to be very hydrophobic. Consequently, large volumes of organic solvents are generally required to maintain solubility and to enable commercial-scale purification. The use of organic solvents raises several toxicological, environmental and regulatory concerns. For example, volatile organic compounds (VOCs) are subject to air quality regulation and organic solvents generally require special handling and disposal. If the active compound is very insoluble in water, then pharmaceutical formulations for internal consumption are generally restricted to formulations as dry powders or solids thus limiting the means by which the medicament can be administered to the patient. For example, water insoluble compounds typically are not used in intravenous (IV) solutions. Therefore, there is a need for a process whereby hydrophobic compounds, such as Echinocandin B, can be selectively made more hydrophilic or aqueous-soluble to reduce or eliminate the need for

SUBSTITUTE SHEET (RULE 26)
organic solvents during the manufacturing process and allows one to easily revert the compounds back to their original state at the end of the process. In addition, there is a need for a method whereby the water-solubility of hydrophobic pharmaceutically active compounds can be increased so that water-based formulations may be used in medicaments without adversely affecting the potency of the drug.

Boronates have been used to purify nucleic acids, carbohydrates and glycoproteins by means of immobilized affinity chromatography. For example, ribonucleosides have been shown to bind via the cis-hydroxyl groups of the ribose to boronate ligands that are attached to an insoluble resin at pH values above the pKa of the boronate. When the pH is lowered, the boronate reverts from a tetrahedral to trigonal planar form and the ribonucleoside is released from the resin. See, i.e., Liu, X.C., et al., J. of Chromatography A, 687, 61-69 (1994); Alvarez-Gonzales, R., et al., Anal. Biochem., 135, 69-77 (1983); Weith, H.L., et al., Biochemistry, 9, 4396-4401 (1970); and Scouten, W.H., Solid Phase Biochemistry, Wiley, New York, p 149 (1983). The purification process requires dissolving or suspending the cis-diol in an alkaline solution which is generally problematic for cyclic peptides due to opening of the ring nucleus. This can be particularly troublesome in a manufacturing process where the process times are lengthy resulting in an increased opportunity for degradation.

**BRIEF SUMMARY OF THE INVENTION**

The present invention provides a reversible boronate/1,2-cis-diol, cyclic-peptide adduct that is more water-soluble than the parent 1,2-cis-diol cyclic-peptide from which it is derived. Surprisingly, the boronate adducts of 1,2-cis-diol cyclic-peptides having the following general structure are significantly more
soluble in aqueous solutions than their corresponding parent cis-diol, cyclic-peptide compound.

wherein R is a hydroxy, an alkoxy group, a phenoxy group, an alkyl group, a phenyl group (e.g., m-aminophenyl or p-carboxyphenyl), a thiol, a thioalkyl group, or a thiophenyl group; R¹ is -H or -C(O)R¹a where R¹a is an alkyl group, an alkenyl group, an alkynyl group, an aryl group, heteroaryl group or combinations thereof; R² is -H or -CH₃; R³ is -H, -CH₃, -CH₂CONH₂ or -CH₂CH₂NH₂; R⁴ is -H or -OH; R⁵ is -OH, -OPO₃H₂, or -OSO₃H; R⁶ is -H or -OSO₃H and X⁺ is any suitable cation (e.g., H⁺, cation of an alkali metal, NH₄⁺, etc. including any pharmaceutically acceptable cations).

The term “aqueous” refers to water as well as homogeneous mixtures of water with organic solvents such as, methanol, ethanol, propanol, acetonitrile, dimethylformamide, dimethylsulfoxide, propylene glycol, polyethylene glycols (e.g., PEG400, PEG300), and the like. Generally, the organic solvent content of
the homogeneous mixture is less than 50% by weight, preferably less than 25%.
more preferably less than 10%, most preferably 0%.

In another embodiment of the present invention, a method is provided for
complexing a boric or boronic acid with a cyclic-peptide compound comprising at
least one 1,2-cis-diol moiety to produce a borate or boronate/cyclic-peptide adduct
including the Echinocandin/boronate adduct described above. As used herein, the
terms “complex”, “complexed” and “complexation” refer to the reaction between
the boric or boronic acid and the 1,2-cis-diol moiety of the cyclic peptide
compound to form the reversible adduct described above. The borate/cis-diol
adduct(1) shown below in the detailed description provides an additional
illustration of a complex with boric acid in a more generic form.
Correspondingly, the terms “decomplex”, “decomplexed” and “decomplexation”
refer to the reverse reaction where the adduct reverts back to its original
components (i.e., the boric or boronic acid and the 1,2-cis-diol, cyclic peptide).

In yet another embodiment of the present invention, a method is provided
for purifying a 1,2-cis-diol cyclic-peptide by providing a crude mixture of a 1,2-
cis-diol cyclic peptide, complexing the 1,2-cis-diol moiety of the cyclic-peptide
with a boric (or boronic) acid to form a borate (or boronate) adduct, solubilizing
the borate adduct in an aqueous solution, removing any insoluble materials from
the aqueous solution, acidifying the aqueous solution to a pH value that is equal to
or less than the pKa of the boric (or boronic) acid, and recovering the 1,2-cis-diol
cyclic-peptide from the acidified solution.

In yet another embodiment, a pharmaceutical formulation is provided
comprising the reversible adduct described above. Of particular interest are
adducts comprising the Echinocandin derivatives described above for treatment of
fungal infections. A method is also provided for treatment of a host in need of
treatment for a fungal infection which includes administration of an therapeutic amount of the reversible borate or boronate/Echinocandin adduct (described above) to a host and decomplexing the adduct to release the pharmaceutically active 1,2-cis-diol, cyclic peptide.

DETAILED DESCRIPTION

It is believed that boric and boronic acids behave in a Lewis acid fashion where they accept a hydroxyl group under alkaline conditions and assume a tetrahedral geometry as depicted below for boric acid.

borate/cis-diol adduct(1)

Unlike the trigonal planar geometry of boric acid in neutral or acidic conditions, the tetrahedral geometry in alkaline conditions enables coupling to 1,2-cis-diols to form a borate/cis-diol adduct(1). By changing the acidity of the solution the adduct becomes reversible. In other words, a borate/diol adduct forms under alkaline conditions and reverts back to the separate starting materials when subjected to acidic conditions. The same is also true for adducts formed with boronic acids.

Since the borate and boronate adducts are ionic in character, the hydrophilicity or water-solubility of the complexed material is enhanced. Hence, materials containing a 1,2-cis-diol moiety that are generally insoluble or only slightly
soluble in aqueous solutions can be made soluble or more soluble in aqueous solutions by forming a borate or boronate adduct. Surprisingly, applicants observed a significant change in water solubility when 1,2-cis-diol cyclic peptides are complexed with boric (or boronic) acid. For example, Example 1 below shows a 10-fold increase in solubility of an Echinocandin B derivative in the presence of m-aminophenyl boronic acid at a pH of 9.0 in an aqueous solution. At concentrations of 30 mg/ml, the aqueous solution of the non-complexed Echinocandin B derivative is an opaque slurry; whereas, the aqueous solution of the boronate complex is a transparent solution. The increased solubility in aqueous solutions provides several advantages. It reduces the amount of organic solvents required in the manufacturing process which decreases costs and regulatory concerns. The process not only reduces the probability of residual solvent in a pharmaceutically active material which may be detrimental to the overall toxicology of a resultant medicament; it also allows one to design water-based pharmaceutical formulations based on the boronate adduct. Due to the ease by which the boronate complex is formed and the increased solubility of the complex, the process also provides a convenient method for assaying samples containing 1,2-cis-diol, cyclic-peptides.

Unlike the parent 1,2-cis-diol, cyclic-peptides, the corresponding borate (or boronate) adducts are more stable at high pHs. Cyclic peptides containing an ornithine unit are known to lose the ornithine unit under alkaline conditions due to the hydroxyl groups. The boronate adduct provides a means of protecting the ornithine unit from fragmentation by complexing with the 1,2-cis-diol moiety. Once the alkaline reaction is completed, the boronate functionality can be easily removed by simply reducing the pH of the solution (or mixture).
The formation of borate (or boronate) adducts is particularly useful for purifying Echinocandin-type antifungal compounds. The following discussion describing Echinocandin-type materials provides a useful illustration for the formation and use of boronate/cyclic peptide adducts. However, it will be understood by those skilled in the art that any cyclic peptide having at least one 1,2-cis-dirol moiety attached to the cyclic ring nucleus can form a boronate adduct and therefore fall within the scope of the present invention.

Any Echinocandin-type natural product or semi-synthetic derivative may be used to form a borate (or boronate) adduct so long as the cis-hydroxyl groups of the ornithine peptide unit are present and not blocked. The ornithine α-amino group may be acylated or non-acylated. As used herein, the term “Echinocandin-type compounds” refers to compounds having the following general structure including any simple derivatives thereof:

wherein R\(^1\) is -H or -C(O)R where R is an alkyl group, an alkenyl group, an alkynyl group, an aryl group, or heteroaryl group; R\(^2\) is -H or -CH\(_3\); R\(^3\) is -H, -CH\(_3\), -CH\(_2\)CONH\(_2\) or -CH\(_2\)CH\(_2\)NH\(_2\); R\(^4\) is -H or -OH; R\(^5\) is -OH, -OPO\(_3\)H\(_2\), or -
OSO₃H; and R' is -H or -OSO₃H. Pharmaceutically acceptable salts, esters and hydrates are also included.

The term "alkyl" refers to a hydrocarbon radical of the general formula CₙH₂ₙ₊₁ containing from 1 to 30 carbon atoms unless otherwise indicated. The alkane radical may be straight, branched, cyclic, or multi-cyclic. The alkane radical may be substituted or unsubstituted. Similarly, the alkyl portion of an alkoxy group or alkanoate have the same definition as above.

The term "alkenyl" refers to an acyclic hydrocarbon containing at least one carbon-carbon double bond. The alkene radical may be straight, branched, cyclic, or multi-cyclic. The alkene radical may be substituted or unsubstituted.

The term "alkynyl" refers to an acyclic hydrocarbon containing at least one carbon-carbon triple bond. The alkyne radical may be straight, or branched. The alkyne radical may be substituted or unsubstituted.

The term "aryl" refers to aromatic moieties having single (e.g., phenyl) or fused ring systems (e.g., naphthalene, anthracene, phenanthrene, etc.). The aryl groups may be substituted or unsubstituted. Substituted aryl groups include a chain of aromatic moieties (e.g., biphenyl, terphenyl, phenynaphthalyl, etc.)

The term "heteroaryl" refers to aromatic moieties containing at least one heteroatom within the aromatic ring system (e.g., pyrrole, pyridine, indole, thiophene, furan, benzofuran, imidazole, pyrimidine, purine, benzimidazole, quinoline, etc.). The aromatic moiety may consist of a single or fused ring system. The heteroaryl groups may be substituted or unsubstituted.

Within the field of organic chemistry and particularly within the field of organic biochemistry, it is widely understood that significant substitution of compounds is tolerated or even useful. In the present invention, for example, the term alkyl group allows for substituents which is a classic alkyl, such as methyl,
ethyl, propyl, hexyl, isoctyl, dodecyl, stearyl, etc. The term group specifically
envisions and allows for substitutions on alkyls which are common in the art, such
as hydroxy, halogen, alkoxy, carbonyl, keto, ester, carbamato, etc., as well as
including the unsubstituted alkyl moiety. However, it is generally understood by
those skilled in the art that the substituents should be selected so as to not
adversely affect the pharmacological characteristics of the compound or adversely
interfere with the use of a medicament containing the compound. Suitable
substituents for any of the groups defined above include alkyl, alkenyl, alkynyl,
aryl, halo, hydroxy, alkoxy, arylxoy, mercapto, alkylthio, arylthio, mono- and di-
alkyl amino, quaternary ammonium salts, aminoaalkoxy, hydroxyalkylamino,
aminoalkylthio, carbamyl, carbonyl, carboxy, glycolyl, glycy1, hydrazino, guanyl,
and combinations thereof.

The term “natural product” refers to those secondary metabolites, usually of
relatively complex structure, which are of more restricted distribution and more
characteristic of a specific source in nature. Suitable natural product starting
materials belonging to the Echinocandin cyclic peptide family include
Echinocandin B, Echinocandin C, Aculeacin Aγ, Mulundocandin, Sporiofungin
A, Pneumocandin A0, WF11899A, and Pneumocandin B0.

Semi-synthetic cyclic peptides are generally prepared by deacylating the
naturally occurring cyclic peptides using procedures known in the art to provide
the corresponding amino nucleus (where R1 is hydrogen). This reaction is
typically carried out enzymatically, by exposing the naturally occurring cyclic
peptide to a deacylase enzyme. The deacylase enzyme may be obtained from the
microorganism Actinoplanes utahensis and used substantially as described in U.S.
Patent Nos. 4,293,482 and 4,304,716, incorporated herein by reference. The
deacylase enzyme may also be obtained from the Pseudomonas species.
Deacetylation may be accomplished using whole cells of *Actinoplanes utahensis* or *Pseudomonas*, the crude or purified enzyme thereof, or using an immobilized form of the enzyme. (see, i.e., EP 460882)

The amino nucleus \( R^1 = H \) is re-acylated using procedures known in the art to provide an Echinocandin-type compound where \( R^1 \) is an acyl group represented by \(-C(O)R\). Acylation of the amino group may be accomplished in a variety of ways well known to those skilled in the art. For example, the amino group may be acylated by reaction with an appropriately substituted acyl halide, preferably in the presence of an acid scavenger such as a tertiary amine (e.g., triethylamine).

The reaction is typically carried out at a temperature between about -20°C to 25°C. Suitable reaction solvents include polar aprotic solvents, such as dioxane or dimethylformamide. Solvent choice is not critical so long as the solvent employed is inert to the ongoing reaction and the reactants are sufficiently solubilized to effect the desired reaction.

The amino group may also be acylated by reaction with an appropriately substituted carboxylic acid, in the presence of a coupling agent. Suitable coupling agents include dicyclohexylcarbodiimide (DCC), N,N’-carbonyldiimidazole, bis(2-oxo-3-oxazolidinyl)phosphinic chloride (BOP-Cl), N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), benzotriazole-1-yloxytritylphosphonium hexafluorophosphate (PyBOP) and the like.

Alternately, the amino group may be acylated with an activated ester of a carboxylic acid such as p-nitrophenyl, 2,4,5-trichlorophenyl, hydroxybenzotriazole hydrate (HOBT-H₂O), pentafluorphenol, and N-hydroxysuccinimide carboxylate esters. Preferred acylating moieties are the 2,4,5-trichlorophenyl and HOBT carboxylate esters. The reaction is typically run 1 to 65 hours at a temperature from about 0°C to 30°C in an aprotic solvent. The
reaction is generally complete after about 24 to 48 hours when carried out at a
temperature between about 15°C to 30°C. Suitable solvents include
tetrahydrofuran and dimethylformamide or mixtures thereof. The amino group is
generally present in equimolar proportions relative to the activated ester or with a
slight excess of the amino group.

A borate or boronate adduct may be formed with any of the foregoing
Echinocandin-type compounds or synthetic intermediates that contain a 1,2-cis-
diol moiety. The adduct is formed by simply mixing the boric acid with the cyclic
peptide materials under basic conditions. The order in which the reagents are
added is not particularly important. However, to minimize potential for
fragmentation of the cyclic peptide ring, preferably the boric acid is added to the
cyclic peptide prior to increasing the pH of the mixture. Like the order of
addition, the temperature at which the reaction is operated also is not particularly
important; however, to minimize potential ring fragmentation, preferably the
reaction is run near or below room temperature (≤ 20°C).

The pH may be increased with any base reagent capable of acting as a
Lewis base with respect to the boric acid. The particular base used is not critical.
Suitable bases include sodium hydroxide, ammonium hydroxide, ammonium
bicarbonate, potassium carbonate, potassium hydroxide and mixtures thereof. The
amount of base added will vary depending upon the particular boric acid or
boronic acid used. Generally, the amount of base added is equal to the
concentration needed to achieve a pH value sufficient to effect optimum
complexation of the boric acid with the 1,2-cis-diol functionality. For most
reactions, the solution is adjusted to a pH between 7.5 and 9.5.

Suitable boric and boronic acid reagents include boric acid, alkylboronic acids
(e.g., ethylboronic acid, propylboronic acid, butylboronic acid, etc.),
heterocycloalkyl boronic acids (e.g., tetrahydrofuranylboronic acid), arylboronic acids (e.g., phenylboronic acid, o-methylphenyl-boronic acid, m-aminophenylboronic acid, p-methylphenylboronic acid, p-carboxyphenylboronic acid, [o-(diisopropylamino)carbonyl]phenylboronic acid, o-formylphenylboronic acid, m-formylphenylboronic acid, p-methoxyphenylboronic acid, p-nitrophenylboronic acid, p-fluorophenylboronic acid, p-bromophenylboronic acid, p-trifluoromethylphenylboronic acid, 4,4'-diphenyldiboronic acid, 1-naphthylboronic acid, etc.), heteroarylboronic acids (e.g., thiophene-2-boronic acid, thiophene-3-boronic acid, 2-formylthiophene-2-boronic acid, 5-chlorothiophene-2-boronic acid, 5-acetylthiophene-2-boronic acid, benzo[b]thiophene-2-boronic acid, benzo[b]furan-2-boronic acid, indole-5-boronic acid, etc.), and the like. m-Aminophenylboronic acid is particularly preferred when complexed with the Echinocandin compound C1 described below in the Examples. Preferably, the substituents on the boronic acid are chosen such that they do not sterically hinder the formation of the tetrahedral configuration so that optimum complexation may occur. Preferably, the boric or boronic acid is chosen such that the optimum pH to achieve complexation is less than 9.0 to reduce the potential for fragmentation of the cyclic-peptide ring. Suitable boronic acids are available from a variety of commercial sources such as TCI America (Portland, OR), Aldrich Chemical (Milwaukee, WI), Lancaster Synthesis (Windham, NH), or alternatively, synthesized using methods described in Beesley et al., *Biochem. J.*, 209, 229-233 (1983) or Matteson, *Acc. Chem. Res.*, 21, 294-300 (1988).

Reversion of the borate (or boronate) adduct back to the original 1,2-cis-diol, cyclic-peptide can be accomplished by acidifying the solution containing the borate adduct with any suitable acid to lower the pH. The choice of acid is not
particularly important so long as the pH can be lowered to a value sufficient to remove the borate from the cis-diol moiety. The optimum pH value will depend on the pKa of the particular boric acid used for complexation. Suitable acids include hydrochloric acid, acetic acid, phosphoric acid, sulfuric acid, and the like.

It will be understood by those skilled in the art that the formation of the borate or boronate adduct provides a useful means of changing the hydrophilicity of any 1,2-cis-diol intermediate or final product. Increasing the hydrophilicity of the 1,2-cis-diol material not only decreases the amount of organic solvents needed in the process, but may also assist in the isolation and separation of the 1,2-cis-diol material from other non-1,2-cis-diol containing materials at any stage of a synthetic process.

The boronate adducts may be used in a variety of purification methods. For example, the increased solubility of the adduct allows one to separate the soluble adduct from other insoluble materials. An example of a simple purification process based on solubility differences would include the following steps: (i) providing a crude mixture of a 1,2-cis-diol cyclic peptide; (ii) complexing the 1,2-cis-diol moiety of the cyclic-peptide with a boric (or boronic) acid to form a borate (or boronate) adduct; (iii) solubilizing the borate adduct in an aqueous solution, (iv) removing any insoluble materials from the aqueous solution, (v) acidifying the aqueous solution to a pH value that is equal to or less than the pKa of the boric (or boronic) acid; and (vi) recovering the 1,2-cis-diol cyclic-peptide from the acidified solution. The removal of insoluble materials in step (iv) can be accomplished by simple filtration or centrifugation followed by decanting of the liquid. Alternatively, the aqueous solution from step (iii) can be concentrated and separated on a reverse-phase chromatography column (high pressure or preparation column) packed with a hydrophobic reverse phase resin (e.g.,
styrene/divinylbenzene resin) and eluted with an aqueous solvent system (e.g., acetonitrile/water, acetic acid/water, etc.).

The fractions from the chromatographic effluents containing the boronate adduct would then be combined and acidified to decomplex the adduct into its original components (boronic acid and the 1,2-cis-diol, cyclic-peptide). The purified cyclic-peptide product can then be recovered using conventional methods such as, filtration, crystallization, solvent extraction followed by evaporative concentration, reverse osmosis, lyophilization, etc.

Theoretically, an anion exchange column would work as well; however, initial studies have shown that the Echinocandin C1/m-APBA adduct (see Example 1) binds too tightly to Q-Sepharose Fast Flow resin and can be removed only by eluting with a solvent system having sufficient acidity to decomplex the boronate adduct. None the less, the boronate adduct has been shown to bind to an anion exchange resin; therefore, anion exchange chromatography would be a viable method for purification. Those skilled in the art would know how to select the proper anion exchange resin to optimize the system.

A reverse purification process is also possible. For example, if one wanted to remove a cyclic peptide impurity that contained a 1,2-cis-diol moiety from a desired compound that did not contain a 1,2-cis-diol moiety, then one could use the same process described above to remove the unwanted 1,2-cis-diol, cyclic peptide.

The water-solubility and reversibility of the boronate adduct makes it attractive for use in aqueous based pharmaceutical formulations, in particular, aqueous intravenous (IV) solutions. The boronate adduct would remain soluble in the water-based medicament during administration to the patient. The active cyclic-peptide material would then be released from the boronate upon subjecttion.
to acidic conditions in the body. Of course, the reversibility of the boronate would occur within the body regardless of the means by which the drug is administered to the patient. Therefore, the boronate adduct is not necessarily restricted to aqueous-based formulations. Other nonaqueous-based medicaments for administration to the patient could be used as well (e.g., capsules, suppositories, powders, etc.).

A typical formulation comprises the boronate/1,2-cis-diol, cyclic-peptide adduct (or its pharmaceutically acceptable salt, ester or hydrate) in combination with a pharmaceutically acceptable carrier, diluent or excipient. The adduct is typically formulated into pharmaceutical dosage forms to provide an easily controllable dosage of the drug and to give the patient an elegant and easily handleable product. Formulations may comprise from 0.1% to 99.9% by weight of the adduct, more generally from about 10% to about 30% by weight.

As used herein, the term "unit dose" or "unit dosage" refers to physically discrete units that contain a predetermined quantity of active ingredient calculated to produce a desired therapeutic effect. When a unit dose is administered orally or parenterally, it is typically provided in the form of a tablet, capsule, pill, powder packet, topical composition, suppository, wafer, measured units in ampoules or in multidose containers, etc. Alternatively, a unit dose may be administered in the form of a dry or liquid aerosol which may be inhaled or sprayed.

The dosage to be administered may vary depending upon the physical characteristics of the patient, the severity of the patient's symptoms, and the means used to administer the drug. The specific dose for a given patient is usually set by the judgment of the attending physician.

Suitable carriers, diluents and excipients are well known to those skilled in the art and include materials such as carbohydrates, waxes, water soluble and/or
swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water, and the like. The particular carrier, diluent or excipient used will depend upon the means and purpose for which the active ingredient is being applied. The formulations may also include wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, sweeteners, stabilizers, perfuming agents, flavoring agents and combinations thereof.

Of particular interest are pharmaceutical formulations containing boronate complexes of Echinocandin-type compounds. Echinocandin-type compounds have been shown to exhibit antifungal and antiparasitic activity such as growth inhibition of various infectious fungi including Candida spp. (i.e., C. Albicans, C. Parapsilosis, C. Krusei, C. Glabrata, C. Tropicalis, or C. Lusitaniaw); Torulopus spp. (i.e., T. Glabrata); Aspergillus spp. (i.e., A. Fumigatus); Histoplasma spp. (i.e., H. Capsulatum); Cryptococcus spp. (i.e., C. Neoformans); Blastomyces spp. (i.e., B. Dermatitidis); Fusarium spp.; Trichophyton spp., Pseudallescheria boydii, Coccioidoides immits, Sporothrix schenckii, etc.

Compounds of this type also inhibit the growth of certain organisms primarily responsible for opportunistic infections in immunosuppressed individuals, such as growth inhibition of Pneumocystis carinii (the causative organism of pneumocystis pneumonia PCP in AIDS and other immunocompromised patients).

Other protozoans that are inhibited by Echinocandin-type compounds include Plasmodium spp., Leishmania spp., Trypanosoma spp., Cryptosporidium spp., Isospora spp., Cyclospora spp., Trichomonas spp., Microsporidiosis spp., etc.

U.S. Patent Nos. 4,293,489; 4,320,052; 5,166,135; and 5,541,160, incorporated herein by reference, describe a variety of N-acyl derivatized Echinocandin compounds that provide varying degrees of antifungal and antiprotozoal activities. Additional examples of active N-acyl derivatized
Echinocandin compounds may be found in EP 359529; 448353; 447186; 462531; and 561639.

A host in need of treatment for a fungal infection may be treated by administering an effective amount of an Echinocandin/borate adduct (or a pharmaceutically acceptable salt, ester or hydrate thereof). Once the Echinocandin/borate adduct is subjected to acidic conditions in the host, the borate adduct decomplexes or reverts back to the original active Echinocandin compound and the corresponding boric acid. For example, the gastric acids in the stomach are more than sufficient to complete the reversion.

A “host” refers to an organism in or on which a parasite lives, deriving its body substance or energy from the host.

A preferred method includes treating a *Candida albicans* or *Aspergillus fumigatus* infection. The term “effective amount” refers to an amount of active compound which is capable of inhibiting fungal activity. The dose administered will vary depending on such factors as the nature and severity of the infection, the age and general health of the host and the tolerance of the host to the antifungal agent. The particular dose regimen likewise may vary according to these factors. The medicament may be given in a single daily dose or in multiple doses during the day. The regimen may last from about 2-3 days to about 2-3 weeks or longer.

A typical daily dose (administered in single or divided doses) contains a dosage level between about 0.01 mg/kg to 100 mg/kg of body weight of an active compound. Preferred daily doses are generally between about 0.1 mg/kg to 60 mg/kg and more preferably between about 2.5 mg/kg to 40 mg/kg.

**EXAMPLES**
Unless indicated otherwise, all chemicals can be acquired from commercial sources (i.e., Aldrich Chemical, Sigma, etc.) in reagent grade or better.

Centrifugation was performed using an IEC benchtop clinical centrifuge equipped with six-place swinging-bucket rotor (for samples > 1.5 ml) and an Eppendorf tabletop centrifuge model 5415C equipped with standard 18-place rotor (for samples ≤ 1.5 ml). HPLC analyses were performed using a Hewlett Packard Liquid Chromatograph Model 1090 equipped with a 0.46 x 25 cm Zorbax™ SB-C8 column. All injections were 10 μl, followed by gradient elution from 40-100% acetonitrile (AcN) over 25 minutes and UV detection at 280 nm. Unless otherwise stated, samples were diluted in 0.25 N acetic acid/AcN prior to injection to facilitate decomplexation and ensure solubility in the HPLC solvent system. All alkaline pH adjustments were made by addition of a 1:1 mixture of ammonium hydroxide and 50% sodium hydroxide. Measurements were taken with a Beckman φ40 pH meter calibrated with pH 7 and pH 10 standards.

The following examples illustrate the enhanced water solubility and chemical stability of the following Compound C1 in the presence of m-aminophenylboronic acid (m-APBA). Compound C1 may be synthesized according to the procedures described in EP 561639.
Example 1

Solubility of Compound C1 in the presence of m-APBA

Crude C1 was suspended at 50 mg/ml (65% potency: 32.5 mg/ml, or 28.5 mM) in 4 ml of either 100 mM m-APBA or 100 mM ammonium bicarbonate (control) at pH 5.0 and pH 9.0. The samples were stirred at room temperature for 2 hours, at which time aliquots were removed and assayed both before and after centrifugation for five minutes at 1,000 x g. All samples were diluted 50-fold prior to HPLC analysis.

At low pH (≤ 8.0), solid suspensions of Compound C1 in m-APBA and in ammonium bicarbonate were visually identical. Both were opaque and contained varying amounts of solid, insoluble material. However, when the pH was adjusted to 9.0 dramatic differences in appearance between the two samples was observed within approximately 30 minutes. The aqueous ammonium bicarbonate control was beige in color and completely opaque; whereas, the sample containing m-APBA turned a transparent, dark brown. When the mixtures were subjected to centrifugation for 5 minutes at 16,000 x g and the resulting supernatants
quantified by HPLC analysis, the concentration of C1 present in the m-APBA supernatant was 23.76 mg/ml (94% of that in the original suspension) and only 2.27 mg/ml (10% of the original suspension) was present in the ammonium bicarbonate control supernatant.

Replacement of m-APBA with either p-carboxyphenyl boronic acid or boric acid provided a boronate or borate complex, respectively, having increased solubility as well.

**Example 2**

*Stability of Compound C1 in m-APBA at Alkaline pH*

Compound C1 was suspended at 100 mg/ml (65% potency: 65 mg/ml (57 mM) in either 250 mM m-APBA or water (control). Separate samples were adjusted to pH 8.0, 8.5, 9.0, 9.5 and 10.0. Aliquots for time-point analysis were removed and diluted 100-fold in 100 mM acetic acid/methanol prior to HPLC injection. Stability was assessed by analysis of main peak purity, since degradation products are known to elute within the HPLC chromatographic window.

Compound C1 exhibited enhanced chemical stability in the presence of m-APBA in comparison to the aqueous control sample. Not only was the overall purity of the C1 sample augmented in comparison to the control, but degradation also occurred more slowly. After 9 hours at pH 9.5, the purity of the aqueous control was less than 70% of the total peak area; whereas, the sample containing m-APBA was in excess of 70% purity after 17 hours.

Replacement of m-APBA with boric acid provided a very stable borate complex. When p-carboxyphenylboronic acid was used, the complex did not appear to be as stable as the other two complexes. It is believed that the cyclic
peptide ring may have partially fragmented during the complexation process due to the higher pH needed to form the complex.
WE CLAIM:

1. A reversible cyclic peptide adduct comprising a boric or boronic acid complexed with a cyclic peptide having at least one 1,2-cis-diol moiety wherein said adduct is more water-soluble than said cyclic peptide having at least one 1,2-cis-diol moiety.

2. The reversible adduct of Claim 1 wherein said boronic acid is selected from the group consisting of alkylboronic acids, heterocycloalkyl boronic acids, arylboronic acids, and heteroarylboronic acids.

3. The reversible adduct of Claim 1 wherein said boronic acid is selected from the group consisting of ethylboronic acid, propylboronic acid, butylboronic acid, tetrahydrofuranylboronic acid, phenylboronic acid, O-methylphenyl-boronic acid, m-aminophenylboronic acid, p-methylphenyl-boronic acid, p-carboxyphenylboronic acid, [o-(diisopropylaminocarbonyl) phenylboronic acid, o-formylphenylboronic acid, m-formylphenylboronic acid, p-methoxyphenylboronic acid, p-nitrophenoxyboronic acid, p-fluorophenoxyboronic acid, p-bromophenoxyboronic acid, p-trifluoromethylphenylboronic acid, 4,4'-diphenyldiboronic acid, 1-naphthylboronic acid, thiophene-2-boronic acid, thiophene-3-boronic acid, 2-formylthiophene-2-boronic acid, 5-chlorothiophene-2-boronic acid, 5-acetylthiophene-2-boronic acid, benzo[b]thiophene-2-boronic acid, benzo[b]furan-2-boronic acid, indole-5-boronic acid.

4. The reversible adduct of Claim 1 having the following structure
wherein R is a hydroxy, an alkoxy group, a phenoxy group, an alkyl group, a phenyl group, a thiol, a thioalkyl group, or a thiophenyl group; R\(^1\) is -H or -C(O)R\(^{1a}\) where R\(^{1a}\) is an alkyl group, an alkenyl group, an alkynyl group, an aryl group, or heteroaryl group; R\(^2\) is -H or -CH\(_3\); R\(^3\) is -H, -CH\(_3\), -CH\(_2\)CONH\(_2\) or -CH\(_2\)CH\(_2\)NH\(_2\); R\(^4\) is -H or -OH; R\(^5\) is -OH, -OPO\(_3\)H\(_2\), or -OSO\(_3\)H; R\(^6\) is -H or -OSO\(_3\)H; and X\(^+\) is a cation.

5. The reversible adduct of Claim 4 wherein R is a \(m\)-aminophenyl group.

6. The reversible adduct of Claim 4 wherein R\(^{1a}\) has the following structure
7. A method for forming a reversible cyclic peptide adduct comprising the steps of

(i) providing an aqueous solution of a boric or boronic acid,
(ii) adding a cyclic peptide compound having at least one 1,2-cis-diol moiety to said aqueous solution, and
(iii) adjusting the pH of said aqueous solution to a value sufficient to effect complexation between said boric or boronic acid and said cyclic peptide compound.

8. The method of Claim 7 wherein said cyclic peptide has the following structure

![Chemical Structure](image)

wherein $R^1$ is -H or -C(O)$R^{1a}$ where $R^{1a}$ is an alkyl group, an alkenyl group, an alkynyl group, an aryl group, or heteroaryl group; $R^2$ is -H or -CH$_3$; $R^3$ is -H, -CH$_3$, -CH$_2$CONH$_2$ or -CH$_2$CH$_2$NH$_2$; $R^4$ is -H or -OH; $R^5$ is -OH, -OPO$_3$H$_2$, or -OSO$_3$H; and $R^6$ is -H or -OSO$_3$H.
9. The method of Claim 7 wherein said boronic acid is selected from the group consisting of alkylboronic acids, heterocycloalkyl boronic acids, arylboronic acids and heteroarylboronic acids.

10. The method of Claim 7 wherein said boronic acid is selected from the group consisting of ethylboronic acid, propylboronic acid, butylboronic acid, tetrahydrofuranylbromonic acid, phenylboronic acid, o-methylphenyl-boronic acid, m-aminophenylboronic acid, p-methylphenyl-boronic acid, p-carboxyphenylboronic acid, [o-(diisopropylamino)carbonyl] phenylboronic acid, o-formylphenylboronic acid, m-formylphenylboronic acid, p-methoxyphenylboronic acid, p-nitrophenylboronic acid, p-fluorophenylboronic acid, p-bromophenylboronic acid, p-trifluoromethylphenylboronic acid, 4,4'-diphenyldibronic acid, 1-naphthylboronic acid, thiophene-2-boronic acid, thiophene-3-boronic acid, 2-formylthiophene-2-boronic acid, 5-chlorothiophene-2-boronic acid, 5-acetyltihpene-2-boronic acid, benzo[b]thiophene-2-boronic acid, benzo[b]furan-2-boronic acid, indole-5-boronic acid.

11. The method of Claim 7 wherein said aqueous solution is adjusted to a pH value between 7.5 and 9.5.

12. A method for purifying a cyclic peptide having a 1,2-cis-diol moiety comprising in the following order the steps of
   (i) providing a crude mixture of a cyclic peptide having a least one 1,2-cis-diol functionality,
(ii) complexing said at least one 1,2-cis-diol functionality of said cyclic peptide with a boric or boronic acid to form a reversible adduct.

(iii) solubilizing said reversible adduct in an aqueous solution,

(iv) removing any insoluble materials from said aqueous solution,

(v) acidifying said aqueous solution to a pH value equal to or less than the pKa of said boric or boronic acid, and

(vi) recovering said cyclic peptide from said aqueous solution.

13. A method of purifying a 1,2-cis-diol cyclic peptide comprising in the following order the steps of

(a) providing a crude mixture of a cyclic peptide having a least one 1,2-cis-diol functionality,

(b) complexing said at least one 1,2-cis-diol functionality of said cyclic peptide with a boric or boronic acid to form a reversible adduct,

(c) solubilizing said reversible adduct in an aqueous solution,

(d) concentrating said aqueous solution to form a concentrate,

(e) absorbing said concentrate onto a reverse-phase hydrophobic resin packed in a chromatography column,

(f) eluting with an aqueous solvent system, and

(g) combining effluent fractions containing said reversible adduct into a single effluent solution,

(h) acidifying said effluent solution to a pH value equal to or less than the pKa of said boric or boronic acid to decomplex said reversible adduct, and

26

SUBSTITUTE SHEET (RULE 26)
(i) recovering said cyclic peptide from said acidified effluent solution.

14. A pharmaceutical formulation comprising a reversible adduct comprising a complex of a boric or boronic acid with a cyclic peptide having a 1,2-cis-diol moiety.

15. The pharmaceutical formulation of Claim 14 further comprising a pharmaceutically inert carrier.

16. The pharmaceutical formulation of Claim 15 wherein said inert carrier is water.

17. The pharmaceutical composition of Claim 14 further comprising a wetting agent, lubricating agent, emulsifier, suspending agent, preservative, sweetener, stabilizer, perfuming agent, flavoring agent or combinations thereof.

18. The pharmaceutical formulation of Claim 14 wherein said reversible adduct has the following structure
wherein R is a hydroxy, an alkoxy group, a phenoxy group, an alkyl group, a phenyl group, a thiol, a thioalkyl group, or a thiophenyl group; $R^1$ is -H or -C(O)R$^{19}$ where $R^{19}$ is an alkyl group, an alkenyl group, an alkynyl group, an aryl group, or heteroaryl group; $R^2$ is -H or -CH$_3$; $R^3$ is -H, -CH$_3$, -CH$_2$CONH$_2$ or -CH$_2$CH$_2$NH$_2$; $R^4$ is -H or -OH; $R^5$ is -OH, -OPO$_3$H$_2$, or -OSO$_3$H; $R^6$ is -H or -OSO$_3$H; $X^+$ is a cation; and pharmaceutically acceptable hydrates, esters and salts thereof.

19. The pharmaceutical formulation of Claim 18 wherein R is a $m$-aminophenyl group.

20. A method for treating a fungal infection comprising in the following order the steps of

(a) providing a host in need of treatment for a fungal infection,
(b) administering an effective dose of a reversible adduct according to Claim 4. and 
(c) decomplexing said reversible adduct to release a pharmaceutically active 1,2-cis-diol, cyclic peptide.

21. The method of Claim 20 wherein said reversible adduct is administered by means of an aqueous solution.

22. The method of Claim 20 wherein said reversible adduct is administered by means of an aqueous IV solution.
C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>WO 97 47645 A (MERCK &amp; CO INC ; LEONARD WILLIAM (US); BELYK KEVIN M (US)) 18 December 1997 (1997-12-18) See especially page 6, compound III; reaction schemes I and II; example 1; claim 1</td>
<td>1-4, 7-11</td>
</tr>
</tbody>
</table>

* Special categories of cited documents:
- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "I" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document relating to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

**"T"** later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

**"X"** document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

**"Y"** document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

**"&"** document member of the same patent family

Date of the actual completion of the international search: 23 December 1999
Date of mailing of the international search report: 12/01/2000
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>US 5 631 364 A (SUNDREHAGEN ERLING ET AL) 20 May 1997 (1997-05-20) the whole document</td>
<td>----</td>
</tr>
</tbody>
</table>
INTERNATIONAL SEARCH REPORT

Box I  Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

   Remark: Although claims 20-22 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. [ ] Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. [ ] Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II  Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. [X] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

[ ] The additional search fees were accompanied by the applicant’s protest.

[ ] No protest accompanied the payment of additional search fees.
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>CZ 9804119 A</td>
<td>12-05-1999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 0912603 A</td>
<td>06-05-1999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HR 970318 A</td>
<td>31-08-1998</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PL 330400 A</td>
<td>10-05-1999</td>
</tr>
</tbody>
</table>